Provided by Tiger Trade Technology Pte. Ltd.

Cytosorbents

0.3700
+0.058918.93%
Post-market: 0.3617-0.0083-2.24%19:26 EDT
Volume:326.44K
Turnover:111.11K
Market Cap:23.24M
PE:-1.28
High:0.3814
Open:0.3190
Low:0.3110
Close:0.3111
52wk High:1.04
52wk Low:0.3000
Shares:62.80M
Float Shares:52.74M
Volume Ratio:3.32
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2901
EPS(LYR):-0.1317
ROE:-336.21%
ROA:-17.12%
PB:-30.94
PE(LYR):-2.81

Loading ...

CytoSorbents CEO Phillip P. Chan acquires common shares worth $104,109.32

Reuters
·
Jun 16

CytoSorbents announces annual shareholder meeting

Reuters
·
Jun 12

Cytosorbents Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

CytoSorbents Q1 FY26 net loss widens to $5.13 million; revenue rises 2% to $8.9 million

Reuters
·
May 14

CytoSorbents Q1 Adj. EPS $(0.05) Beats $(0.06) Estimate, Sales $8.864M Miss $9.363M Estimate

Benzinga Earnings
·
May 14

BRIEF-CytoSorbents Q1 Revenue USD 8.864 Million

Reuters
·
May 14

Cytosorbents Q1 Product Gross Margin 69%

THOMSON REUTERS
·
May 14

Cytosorbents Q1 EPS USD -0.08

THOMSON REUTERS
·
May 14

Cytosorbents Corp: Unexpected Disruption Due to U.S.-Iran War Has Slowed Anticipated Growth of Recently Established Units in Dubai, UAE

THOMSON REUTERS
·
May 14

Cytosorbents Corp expected to post a loss of 5 cents a share - Earnings Preview

Reuters
·
May 12

Cytosorbents Corp expected to post a loss of 5 cents a share - Earnings Preview

Reuters
·
May 01

CytoSorbents to report first-quarter results after market close May 13

Reuters
·
Apr 30

CytoSorbents wins Nasdaq extension to regain $1 minimum bid compliance

Reuters
·
Apr 02

Cytosorbents Corp - Considering Options Including Reverse Stock Split to Regain Compliance - SEC Filing

THOMSON REUTERS
·
Apr 02

Cytosorbents Corp - on April 1, Granted 180-Day Extension to Regain Nasdaq Minimum Bid Price Compliance - SEC Filing

THOMSON REUTERS
·
Apr 02

Cytosorbents’ Earnings Call Balances Progress and Risk

TIPRANKS
·
Mar 27

Cytosorbents Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 27

Cytosorbents Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 26

CytoSorbents 2025 revenue rises, net loss narrows

Reuters
·
Mar 26

CytoSorbents Q4 Adj. EPS $(0.07) Misses $(0.05) Estimate, Sales $9.234M Miss $9.587M Estimate

Benzinga Earnings
·
Mar 26